Posted by M.Popov on 12th Nov 2020
Trial size ARFGAP1 antibodies available in the Antibody Validation Project
Trial size ARFGAP1 antibodies available in the Antibody Validation Project
Introduction:
ADP ribosylation factor GTPase activating protein 1 is the protein synthesised from the ARFGAP1 gene. This protein is mainly found inside the Golgi apparatus interacts with ADP-ribosylation factor 1 and promotes hydrolysis of GTP bound to that factor. The protein can be found throughout the body and some of the medical conditions related to it are the Parkinson's disease and ALPS. St John's Laboratory offers a variety of trial size primary antibodies which target ARFGAP1, which are available to try through the Antibody Validation Project. Below we highlight those which have already been reviewed, as well as others which are available to try.
- What is ARFGAP1?
- Where is ARFGAP1 found?
- What role does ARFGAP1 play in disease?
- ARFGAP1 antibodies in the Antibody Validation project
- Customer reviewed ARFGAP1 antibodies
- Other ARFGAP1 antibodies available in the Antibody Validation Project
- Popular ARFGAP1 antibodies not currently in the Antibody Validation Project
- How does the Antibody Validation Project work?
What is ARFGAP1?
The protein encoded by this gene is a GTPase-activating protein, associated with the Golgi apparatus and which interacts with ADP-ribosylation factor 1. The protein promotes hydrolysis of ADP-ribosylation factor 1-bound GTP and is required for the dissociation of coat proteins from Golgi-derived membranes and vesicles, which is required for the fusion of these vesicles with target compartments. The activity of this protein is stimulated by phosphoinosides and inhibited by phosphatidylcholine, and alternative splicing results in multiple transcript variants.
Where is ARFGAP1 found?
The ARFGAP1 protein is mainly found in the Golgi apparatus and vesicles on cellular level, and has ubiquitous cytoplasmic expression with a granular pattern in the majority of the tissues.
What role does ARFGAP1 play in disease?
ARFGAP1 takes part in the Parkinson's disease by binding to LRRK2 via the kinase domain and increases its activity and regulates LRRK2 toxicity. It also has been proven to exist in higher concentrations in patients suffering from Autoimmune Lymphoproliferative Syndrome(ALPS)
ARFGAP1 antibodies in the Antibody Validation project
St John's Laboratory offers a variety of trial size primary antibodies which target ARFGAP1, which are available to try through the Antibody Validation Project. Below we highlight those which have already been reviewed, as well as others which are available to try.
Customer reviewed ARFGAP1 antibodies
| Model | Name | Host | Clonality | Rating | Application Tested |
|---|---|---|---|---|---|
| STJ91671 | ARF GAP1 antibody | Rabbit | Polyclonal | 4 | IHC |
Other ARFGAP1 antibodies available in the Antibody Validation Project
Currently we do not have any other ARFGAP1 in the AVP.
Popular ARFGAP1 antibodies not currently in the Antibody Validation Project
| Model | Name | Host | Clonality | Recommended Applications | ||
|---|---|---|---|---|---|---|
| STJ114469 | Anti-ARFGAP1 Antibody | Rabbit | Polyclonal | WB,IHC,IF | ||
| STJ29198 | Anti-ARFGAP1 Antibody | Rabbit | Polyclonal | WB,IHC,IF |
How does the Antibody Validation Project work?
In order to help our customers with their choice of antibody with low risk, we offer one of the largest ranges of primary antibodies with trial size options available.
The Antibody Validation Project works like this.
1. Order your trial size antibody online.
2. Explore its suitability.
3. Return your results by posting them on the product page.
4. Receive a sample refund.
Find out more here.